

August 6, 2025

Company name: ROHTO Pharmaceutical Co., Ltd.

Representative: Hidetoshi Segi,

President and Representative Director

(Code: 4527 TSE Prime)

Contact: Masaya Saito, Vice President and CFO

(TEL: 06-6758-8223)

Notice of Revision of Earnings Forecast

ROHTO PHARMACEUTICAL CO., LTD. (the “Company”) hereby announces that, in light of the recent trends in business performance, the Company has revised its consolidated earnings forecast announced on May 13, 2025.

The forecast indicated below is also disclosed in the “Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2026 (Three Months Ended June 30, 2025) [Japanese GAAP].”

1. Revisions to the earnings forecast

(1) Details of the revisions

Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026)

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast (A) (Announced on May 13, 2025)	334,500	39,000	40,500	31,100	137.63
Revised forecast (B)	334,500	39,000	43,000	31,500	139.40
Change (B-A)	0	0	2,500	400	
Percentage change (%)	0.0	0.0	6.2	1.3	
(Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2025)	308,625	38,234	39,725	30,841	135.38

(2) Reasons for the revisions

The Company has revised the consolidated financial earnings forecast announced on May 13, 2025 to reflect dividend income recorded in the first quarter. Ordinary income and profit attributable to owners of parent are expected to exceed the previous forecast. The expected exchange rates remain unchanged at 142 yen to the US dollar and 19 yen to the Chinese yuan.

*Previous period results are calculated based on figures after retrospective adjustments, reflecting the finalization of the provisional accounting treatment for the business combination conducted in the first quarter of the fiscal year ending March 31, 2026.

*The above forecasts are based on information available as of the date of announcement. Actual results may differ from the forecasts due to various factors.

Rohto Pharmaceutical Co., Ltd.